|
 Astra said on Wednesday its Lynparza drug, which blocks a cancer's
ability to repair its genetic code during cell division, was shown
to slow the progression of ovarian cancer that has started to spread
in the body.
The patient group that was examined in the so-called Paola-1 trial
had been successfully given chemotherapy and Roche's Avastin as
initial treatment following a diagnosis of advanced ovarian cancer.
Those patients then normally receive Avastin as maintenance therapy
to reinforce the initial regime and the study's aim was to show an
advantage of adding Lynparza during the follow-up phase.
[to top of second column] |
Lynparza, part of a class of drugs known as PARP inhibitors, is
already approved as a maintenance therapy in a different
ovarian-cancer patient group that has received chemotherapy alone as
initial treatment.
Domestic rival GSK's Zejula, also a PARP inhibitor, last month
showed promise in a similar treatment setting.
Astra said detailed trial results would be presented at a medical
conference which the company did not specify.
(Reporting by Ludwig Burger; Editing by David Holmes)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
